# A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

> **NCT01571648** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 5 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Oral azacitidine

## Key facts

- **NCT ID:** NCT01571648
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-01
- **Primary completion:** 2013-01-01
- **Final completion:** 2013-01-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571648, "A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01571648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*